Providers

ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.

Naim Alkhouri, MD, discusses real-world resmetirom data in MASH, GLP-1 combinations, and using ANTICIPATE-NASH in practice.

Although smaller studies have highlighted CAR T differences in access and outcomes, new research shows the full extent of the issue.

Nancy Lin, MD, explores MMAI validation needs, turnaround advantages, equity implications, and how payers should approach AI-based diagnostics.

Post-AKI care requires tiered monitoring and medication holds, yet awareness gaps persist among patients and clinicians, said Thai Dang, MD.

Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy.

Nancy Lin, MD, explains how an AI model compares with genomic classifiers in HR+/HER2- early breast cancer, with implications for cost and access.

State data reveal 2026 ACA marketplace enrollment losses are accelerating post open enrollment, as cancellations surge and affordability pressures mount after tax credits expired.

Rural America has 44% fewer health care workers per capita than urban areas, with psychologists and physicians hit hardest.

PROTEUS results reshape high‑risk localized prostate cancer care, adding apalutamide plus androgen deprivation before surgery as a new option.

OPTIMA trial data show genomic testing helps many patients with high‑risk breast cancer skip chemotherapy safely and start endocrine therapy sooner.

Chronic inflammation, hormonal imbalance, and surgical management all deplete ovarian reserve in endometriosis patients, a new systematic review finds.

Chemotherapy decisions for young women with HR+ breast cancer and low recurrence scores reveal testing disparities that health systems must address.

An AI-driven review of oncology trials reveals that diversity progress over 30 years is largely an illusion driven by Asian enrollment growth.

Longer-term data support pimicotinib as an effective, well-tolerated option for a rare benign tumor that can cause significant joint disability.

ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens.

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs with fewer visits.

Closing the gap between CKD detection and treatment requires aligned screening, streamlined pathways, and equitable access to proven therapies.

Community oncology practices face major infrastructure and reimbursement gaps when delivering bispecific antibodies.

Real-world data suggest nirogacestat boosts response in desmoid tumor vs standard-of-care treatment, but small cohorts leave key outcomes unanswered.

Medicare’s GLP-1 Bridge offers temporary coverage for obesity medication at $50/month, but patients face a 2027 cliff as BALANCE stalls.

From biased trial enrollment to the emotional weight of a young diagnosis, Rani Bansal, MD, speaks to the gaps we need to close.

ARACOG trial data highlight cognitive effects of ARPIs in prostate cancer, showing less cognitive decline with darolutamide than enzalutamide, notes Alicia Morgans, MD, MPH.

Teclistamab bispecific from Johnson & Johnson boosts early-line multiple myeloma outcomes, fueling safer outpatient therapy options.

Health plan infrastructure and patient reporting are underutilized, powerful tools for identifying food insecurity, Jonathan Wrathall, PhD, argues.